skip to Main Content


Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."


United Healthcare Home Immunotherapy Policy Change

United Healthcare has recently announced a policy change. Effective January 1, 2023, UHC will no longer…

Read more

Medicare 2022 Conversion Factor Update

Thanks to lobbying efforts from the House of Medicine, Congress took action this month. The…

Read more

CY 2022 Physician Fee Schedule Proposed Rule Summary

On July 13, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

Read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/01/23: Fellow Exam Application Deadline
Learn more

06/01/23: Research Grant Cycle
Learn more

06/26/23: Membership Application Deadline to be eligible for AAOA Member rate for the 2023 Basic Course

07/01/23: Scientific Abstract Submission Deadline
Learn more

12/01/23: Research Grant Cycle
Learn more


2023 AAOA Basic Course

The hybrid 2023 AAOA Basic Course in Allergy & Immunology will take place from Thursday, June 29 – Saturday, July 1, 2023 at the Hyatt Regency, Seattle, WA & Virtually. The Pre-Work On-Demand content will be released on Thursday, June 1, 2023. The Post Course On-Demand Access will be available until September 1, 2023. Learn More and Register Today


For information about Resident opportunities, DosedDaily, research grants, and other resources. Learn More


Available Now


IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

AAOA Educational Stacks
Next Availability - November 1, 2023

2023 AAOA Advanced Course in Allergy & Immunology - Hybrid
March 30 - April 1, 2023
The Hythe Vail
Formerly the Vail Marriott Mountain Resort
Learn More and Register

2023 AAOA Basic Course in Allergy & Immunology - Hybrid
June 1 - Pre-Work On-Demand
June 29 – July 1 - Live
September 1 - Access
Hyatt Regency Seattle
Learn More and Register

2023 AAOA Annual Meeting - Hybrid
September 29 – October 1, 2023
Embassy Suites by Hilton Nashville Downtown
Learn More and Register

USP 797 Online Module
Learn More and Register

News and Updates

American Elm Shortage

American Elm is dying from Dutch Elm Disease. This may explain the concentrate shortage many practices…

Read more

USP General Chapter Released

After a multi-year effort, the long-awaited revision of Chapter 797 Standards for Sterile Compounding (797) of…

Read more
College Allergy Symptoms Treatment Back to Shcool


AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More


AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>


Additional COVID-19 Relief Up in the Air

House Speaker Nancy Pelosi (D-CA) and Treasury Secretary Steven Mnuchin appeared to be moving closer to a deal on a fourth major COVID-19 relief bill before the election—they were approximately $300 billion apart on a package. However, the results of the November election leave prospects for an additional relief package very much up in the air. 

President-elect Joe Biden’s victory over President Donald Trump has scrambled the negotiations. Despite tweets from President Trump urging Congress to reach a deal, the White House, including Secretary Mnuchin, has essentially pulled out of the negotiations, leaving Speaker Pelosi to negotiate additional relief with Senate Majority Leader Mitch McConnell (R-KY) who has a different approach to relief than the Speaker. Last week Leader McConnell proposed an additional $500 billion in relief, saying a larger package was not necessary in light of the news about the Pfizer vaccine and the better-than-expected jobs report; Pelosi is still advocating for a package worth over $2 trillion. She and Senate Minority Leader Chuck Schumer (D-NY) have spoken to President-elect Biden who is supportive of another relief deal and is making the COVID-19 response one of his top priorities as he prepares to take office in January.

How Speaker Pelosi and Majority Leader McConnell bridge this gap is unclear. Both have advocated for passing another package in the lame-duck session of Congress. At this point, we anticipate any additional relief deal will need to be considered by December 11, the same date that government funding is set to expire. We know that Majority Leader McConnell has expressed a willingness to support additional state and local aid, one of the Speaker’s top priorities. Her other priorities include support for testing and contact tracing, increased unemployment aid, and additional funding for the Paycheck Protection Program with new money for small business loans. Majority Leader McConnell’s top priority is liability protections that would apply to businesses as well as medical providers.

Action on Physician Fee Schedule Cuts Also Uncertain

The Centers for Medicare & Medicaid Services’ (CMS) Medicare Physician Fee Schedule (MPFS) proposed rule included how the agency planned to adjust the conversion factor to maintain budget neutrality in light of the increases to the outpatient evaluation and management (E/M) codes scheduled for January 1, 2021; it proposed a 10.6 percent cut to the conversion factor, reducing it from approximately $36 to approximately $32.26. The proposed conversion factor is below the 1994 conversion factor of $32.90—that is worth approximately $58.02 today. The physician community knew that the redistributive impact of the E/M policy would be significant when it was finalized in the 2020 MPFS, but did not expect to absorb such a significant cut in the middle of a global pandemic. 

Congress is now considering if and how to intervene and address these cuts. Their efforts are complicated by the delay in the release of the final MPFS. The final rule typically is released around November 1, but is expected on December 1 this year as a result of the delay in the release of the proposed rule this summer. So far, two legislative options have emerged: H.R. 8505 introduced by Representatives Michael Burgess (R-TX) and Bobby Rush (D-IL) and H.R. 8702, the Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020, introduced by Representatives Ami Bera (D-CA) and Larry Bucshon (R-IN). 

H.R. 8505 would waive the budget neutrality requirement in 2021, which would allow all MPFS services to be paid at the 2020 conversion factor. The cost of this would be paid for using unspent funds from the Provider Relief Fund. H.R. 8702 would provide MPFS services that would be paid less in 2021 and 2022 than they were in 2020 with a hold harmless payment to make up the difference in payment. All of the outpatient E/M services when billed with GPC1X, the complexity add-on, and CPT codes 99212-15 would be specifically excluded from these hold harmless payments.

While H.R. 8505 would provide relief to all providers, members of Congress are generally not supportive of using Provider Relief Fund dollars as an offset. There are also concerns about how to pay for H.R. 8702, but this bill has also divided the house of medicine—those who typically bill outpatient E/M services and do not bill procedures have expressed strong opposition and those who bill procedures are supportive. If and how this will be resolved is unclear at this point. CMS may address the conversion factor in the final rule when it is released, which could change the legislative calculus. Should Congress act, we expect this will be addressed in the end-of-year legislative package that needs to pass by December 11 when funding for the government is set to expire.

Back To Top